A Phase 2 interventional study of Ivarmacitinib and Placebo in T1DM - Type 1 Diabetes Mellitus, sponsored by Huijie Zhang. Not yet recruiting at 1 site in China. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Huijie Zhang · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Diabetes Mellitus, Type 1 with a site in China — 42 open to participants now, 45 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · China.
Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, this one is the 24th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 41 of the 44 other live ones, and was the 102nd registered.
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →42 of the 103 studies in Diabetes Mellitus, Type 1 with a site in China are open now. Recruiting first, the newest first:
SiBionics, Co, Ltd · Sites in China
Ages 18+
Nanjing Medical University · Sites in China
Ages 18–65
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 14–65
Nanjing Medical University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 10 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 18 · Phase 3 13 · Phase 4 13
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 132 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 83 interventional studies, 500 across the 20 observational. Of the 33 that completed or were terminated, 10 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 103 have an industry lead sponsor. The 10 most frequent:
Huijie Zhang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Huijie Zhang has 1 study filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
10 of the studies in Diabetes Mellitus, Type 1 with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708780The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolImmunotherapy with Autologous Tregs in T1DM | 2026-12 |
| NCT06496412Second Xiangya Hospital of Central South UniversitySafety and Efficacy of Fecal Microbiota Transplantation on Cognitive Function in T1DM | 2026-12-30 |
| NCT06198725Children's Hospital of Fudan UniversityIntervention for Children With Type 1 Diabetes Targeting Gut Microbes | 2026-12-31 |
| NCT07051564Zibo Central HospitalClinical Study on the Treatment of Type 1 Diabetes With CNK-UT009 Cell Injection | 2026-12-31 |
| NCT05294653Shanghai Jiao Tong University School of MedicineAtherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 103 studies in Diabetes Mellitus, Type 1 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, placebo-parallel-controlled, multicenter study. The objective is to evaluate the efficacy and safety of Ivarmacitinib 8 mg administered for 52 weeks in preserving pancreatic β cell function in subjects with newly-onset type 1 diabetes mellitus. The study consists of a screening period (V1, up to 2 weeks), a 52-week double-blind treatment period (V2 to V14), and a 4-week safety follow-up period (V15).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ivarmacitinib
Drug: Placebo
Oral tablet, administered at a fixed dose of 8mg once daily for 52 weeks.
Oral tablet matching active Ivarmacitinib in appearance and scheduling, without active ingredients, taken once daily for 52 weeks.
Change from baseline in MMTT-stimulated C-peptide AUC at Week 52
Change from baseline in C-peptide area under the curve (AUC) during a mixed-meal tolerance test (MMTT) after 52 weeks of treatment.
Time frame: From Baseline to Week 52
Change from baseline in MMTT-stimulated C-peptide AUC at Week 26
Change from baseline in C-peptide area under the curve (AUC) during a mixed-meal tolerance test (MMTT) after 26 weeks of treatment.
Time frame: From Baseline to Week 26
Change from baseline in HbA1c at Week 52
Change from baseline in glycated hemoglobin (HbA1c) after 52 weeks of treatment.
Time frame: From Baseline to Week 52
Change from baseline in daily insulin dose at Week 52
Change from baseline in daily insulin dose after 52 weeks of treatment
Time frame: From Baseline to Week 52
Change from baseline in TIR assessed by CGM at Week 52
Change from baseline in time-in-range (TIR) assessed by continuous glucose monitoring (CGM) after 52 weeks of treatment.
Time frame: From Baseline to Week 52
Cumulative severe hypoglycemic events from baseline to Week 52
Total number of severe hypoglycemic events that occurred during 52 weeks of treatment.
Time frame: From Baseline to Week 52
Change from baseline in lymphocyte subpopulation quantified by flow cytometry at week 52
Peripheral Blood Mononuclear Cell (PBMC) will be isolated and lymphocyte subpopulation will be quantified at baseline and Week 52
Time frame: From Baseline to Week 52
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication.
Access criteria: IPD and supporting information will be available to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Aug 2029, 35 months later.
Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 35 months is below that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivarmacitinib
Huijie Zhang